HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to.

Slides:



Advertisements
Similar presentations
“ The therapeutic effect of FIT- 06, GTU®-Multi-HIVB DNA vaccine, observed in HIV-1 infected people. Results of a Phase II trial”. Prof. Mart Ustav SVP,
Advertisements

Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.
A5336 A Phase IIa, Double-blind, Placebo-controlled, Randomized Trial of Ruxolitinib in Antiretroviral-treated HIV-Infected Adults CAB Draft Discussion.
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
Phase 2 of new ARVs BMS (maturation inhibitor)
Cell- and Tissue-based Measures of Viral Persistence Are Associated with Immune Activation and PD-1-Expressing CD4+ T cells H Hatano 1, V Jain 1, PW Hunt.
HIV-1 DNA levels after antiretroviral therapy in primary infection predict disease progression: the SPARTAC Trial James Williams 1,2,3, Jacob Hurst 1,2,3,
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
Cancer vaccines are biological response modifiers. They prime the immune system to attack the cancer cells in the body. The goal is to prevent or to treat.
Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV-1 env gene influences HIV replication and evolution.
Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy S. Fourati 1, R. Calin 2, G. Carcelain 3, P.
Immune correlates of unusual control of viral replication after cessation of HAART Ellen Van Gulck 1, Leo Heyndrickx 1, Céline Merlin 1, Sandra Coppens.
Long-term ART initiated during primary HIV-1 infection limits the HIV-1 reservoir size but not to levels found in LTNPs Eva Malatinkova, Ward De Spiegelaere,
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
Projeto Praça Onze Universidade Federal do Rio de Janeiro Clinical Trials at AIDS Vaccine ‘09 Scientific Journalists Training Program Global HIV Vaccine.
Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.
Safety and effect of an extract from Ganoderma lucidum (Reishi) on NK cell numbers in HIV+ individuals not taking antiretroviral therapy. JT Leonard 1,
Overview Pediatric HIV Program & IMPAACT/ PACTG Vaccine Research Children’s National Medical Center, Washington, DC Dr.Hans ML Spiegel Director Special.
Novel Approaches: Treatment and HIV Pathogenesis L. Trautmann, Ph.D. VGTI Florida.
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.
Increased clinical events in HIV-infected patients who achieve full virologic suppression but fail to attain a CD4 count ≥ 200 cells/mm 3 after one year.
Clinical Aspects of Treatment with Tipranavir Dr Kevin Curry Boehringer Ingelheim, Bracknell, UK.
Poster # 388 CROI Feb Montreal, Canada Association of HIV-1 Co-receptor Tropism with Immunologic and Virologic Parameters in HIV-1 infected,
IAC 2006 Abs# THLB0214 Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, as part of Combination ART in Treatment -Naïve HIV-1.
Neurocognitive Impairment in HIV-Infected Subjects on HAART: Prevalence and Associations Kevin Robertson *1, Kunling Wu 2, Thomas Parsons 1, Ron Ellis.
Yerkes National Primate Research Center
Association between CSF and peripheral markers of immune- activation/inflammation and elevated intratechal HIV–RNA levels in a cohort of.
Twice Weekly Peg-IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-Infected African American Patients Alison.
The Use of Pooled Viral Load Testing to Identify Antiretroviral Treatment Failure Davey Smith 1, Susanne May 2, Josué Perez-Santiago 1, Matthew Strain.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500.
11 NAPWA Symposium 6 th IAS Meeting An HIV-based Lentiviral Vector Vaccine Achieves Functional Cure Post-challenge in a Subset of Vaccinated Macaques Dr.
1 The impact of ongoing illicit drug use on virologic suppression in HIV-infected injection drug users receiving HAART Authors: Harout Tossonian, Jesse.
12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.
Clinical development programme for Second-Line treatment Anton Pozniak World AIDS Conference, July 2014.
Safety and Efficacy of Abbreviated Induction with Oral Fludarabine (F) and Cyclophosphamide (C) Combined with Dose-Dense IV Rituximab (R) in Previously.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Randomized Therapeutic Vaccine Trial of Canarypox-HIV (CP-HIV) + Dendritic Cells vs. CP-HIV Alone in HIV- infected Patients on Antiretroviral Therapy:
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
Conclusions Materials and Methods Background Objectives HIV-1 RNA is the most significant determinant of cervical HIV-1 shedding. Shedding has also been.
Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.
Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection The INSIGHT START Study Group Ben Andres Oct 15, 2015.
Neurologic Effects Associated With Efavirenz Generally Mild, Transient Slideset on: Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological.
POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.
Background  HIV-1 infection persists in reservoirs and leads to progressive depletion of CD4+ T-cells even in subjects with slow disease progression 
Slideset on: Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in.
Improving Patients Retention in Antiretroviral Treatment Programs: The experience of ARV Programs in Côte d’Ivoire Eugène MESSOU, MD, PhD CePReF- Aconda.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.
Telbivudine Versus Lamivudine in Chinese Patients with Chronic Hepatitis B: Results at 1 Year of a Randomized, Double-Blind Trial HEPATOLOGY 2008;47:
PPD Global Feasibility Services
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
Treatment-Naïve Adults
Catherine K. Koofhethile 21st IAS July,2016 Durban, SA
coinciding with biphasic immune reconstitution
Etravirine in Treatment Experienced DUET-2 (TMC125-C216)
Higher rate of antiretroviral therapy reinitiation among HIV-HBV coinfected patients in the episodic arm of the SMART study Dore G.1, Soriano V.2, Neuhaus.
Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227
Dolutegravir + ABC-3TC and CSF HIV-1 RNA Levels ING Study
Atazanavir + ritonavir vs. Lopinavir-ritonavir CASTLE Study
MHEALTH to Improve Health: Effectiveness of a weekly text messaging intervention to improve ART adherence and HIV Viral Load: WelTel OAKTREE. M.C.M. Murray1,2,3,
J. P. Routy1, V. Mehraj1,, R. Ramendra1,, C. Costiniuk1,, B
HIV-1 specific restriction factors increase in response to viral rebound after analytical treatment interruption De Scheerder Marie-Angélique, Van Hecke.
Association of HIV-1 replication fitness, as measured in a whole-virus parallel infection assay, with ability to control viremia after treatment interruption.
Presentation transcript:

HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to pre-ART viral load) and delay in the time to viral rebound during a 12 week structured treatment interruption (STI) J.P. Routy 1, J. Angel 2, S. Vezina 3, C. Tremblay 4, M. Loutfy 5, J. Gill 6, J.-G. Baril 7, F. Smaill 8, R. G. Jain 9, I. Y. Tcherepanova 9, M.-R. Boulassel 10, T. Monesmith 9, R. P. Sekaly 11, C. A. Nicolette 9, and AGS Study Group 1 McGill University Health Centre, INSERM Unit 743, Montréal, Canada, 2 Ottawa Hospital, Ottawa, Canada, 3 Clinique Médicale l'Actuel, Montréal, Canada, 4 Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada, 5 Maple Leaf Clinic, Toronto, Canada, 6 Southern Alberta Clinic, Calgary, Canada, 7 Clinique Medicale du Quartier Latin, Montréal, Canada, 8 Hamilton Health Sciences - McMaster University Medical Centre, Hamilton, Canada, 9 Argos Therapeutics Inc, Durham NC, United States, 10 McGill University Health Centre, Montréal, Canada, 11 University of Montréal Research Centre, Montréal, Canada Funded by NIAID, NIH (NO1-A ), CTN-CIHR #239 and Argos Therapeutics, Inc.

Background and rationale ART represents a major breakthrough for the management of HIV-infected patients, however is not without side effects and is a life long commitment Therapeutic vaccines to enhance immune response and control viral replication are needed to limit exposure to ART AGS-004, (Argos Therapeutics) which consists of autologous monocyte-derived dendritic cells co-electroporated with in vitro transcribed RNA encoding four of the patient’s own HIV antigens (Gag, Vpr, Rev, and Nef) was developed A phase 1 study demonstrated CTL induction without activating CD4 + T cells (Routy et al. Clin Immunol 2010 )

Study Design: Phase 2 AGS-004 dosing every 4 weeks 8 weeks12 weeks ART 12 Week STI Booster Phase ART Study design: Single-arm, open-label, multicenter, Phase 2 study to assess safety and antiviral activity of AGS doses of AGS-004 while on ART, 2 doses off ART and then dosed when VL< copies/ml End points: Time to VL rebound, Pre-ART vs. Wk 12 of STI change in VL, tolerance, restart ART when CD4 < 350 /mm 3 Key Criteria: First ART with VL <50 copies/ml, CD4 ≥450/mm 3 for at least 90 days, nadir ≥200/mm 3 Booster phase if VL < copies/ml

Time from ART Interruption to Viral Load Rebound, n=22 Median time to viral load rebound (≥50 copies/mL) = 3.86 weeks Mean time: 3.77 weeks  22 Patients out of 29 who received AGS-004 immunotherapy: Interim analysis Blood sampling q 2 weeks Increase in the proportion of patients with VL rebound ≥ day 14 was seen from historical control. Swiss cohort, Fischer et al. AIDS 2003; 17; 195 Fisher’s exact test, the p-value for the difference = 

The median reduction for responders (n=14) was log No association between the change in viral load and susceptible (B*31, B*45, B*35) or protective (B*27, B*51, B*57) HLA alleles Pre-ART vs. Week 12 of STI Log Change in Viral Load N=22 Mean reduction in viral load log (n=22) For those who had lower VL than pre-ART(n=14) Mean reduction in viral load = log

Conclusion Administration of AGS-004 immunotherapy: Feasible in a multicenter study Safe, with no additional risk observed during STI Long delay in viral rebound Lower viral load when compared to pre-ART levels CD4 T cell counts: No significant decrease from the median of the last three CD4 + T cell counts on ART vs. in the STI (p-value = 0.20) Immune correlate: – CD8 T-cells was consistent with an effector/memory response – Absence of CD4 induced activation – Poster THPE0181, C Nicolette These results warrant further evaluation: – Phase 2 b, NIH-supported double-blind, placebo-controlled, randomized study, AGS in US and Canada